PRESENTATION

Q2 2021 — Presentation

Q2 2021PDF · 17 pages1.2 MB
Merck
Q2 2021 Earnings

-- 1 of 17 --

Forward-looking statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
2
This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive
the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability
to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020
Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site
(www.sec.gov).

-- 2 of 17 --

$11.4B
+19%
Q2 performance highlights
3
Advanced
the
pipeline 5
1. Growth rates exclude impact of foreign exchange
2. The GAAP to non-GAAP reconciliation is available in the Supplemental Tables to Merck’s Q2 2021 earnings release.
3. GAAP EPS =$0.48
4. Results are presented on a continuing operations basis
5. Key milestones through July 29, 2021
Worldwide
sales
performance1,4
• 	Invested $2.5B in research and development, making
significant progress in advancing our pipeline and
sustaining our key growth pillars
• 	Returned $1.9B to shareholders through dividends and
share repurchase
• 	Completed spinoff of Organon on June 2, received cash
distribution of approximately $9B
$1.31
+27%
Non-GAAP
EPS
performance1,4
Created
shareholder
value
• 	FDA approved 4 filings in oncology and vaccines and granted 2
priority reviews in oncology
• 	In the EU, received 2 approvals for KEYTRUDA and one
approval for Verquvo
• 	In China, received 2 approvals in oncology
• 	Presented data at ASCO, ESMO Virtual Plenary, ECCMID, and
IAS
• 	Toplined results for KEYTRUDA and VAXNEUVANCE
• 	Advanced COVID-19 antiviral into 2 Phase 3 trials

-- 3 of 17 --

Driving value for patients and shareholders by progressing our pipeline
Key regulatory milestones through July 29:
• 	In the U.S., received approval for KEYTRUDA in high-risk early-stage TNBC based on KN-522, in gastric or GEJ
cancer based on KN-811, in endometrial cancer based on KN-775, and in locally advanced cSCC based on KN-629,
as well as received approval for pneumococcal conjugate vaccine VAXNEUVANCE (V114) in adults
• 	In the U.S., FDA granted priority reviews for KEYTRUDA + Lenvima in RCC based on KN-581
• 	In the EU, received approval for Verquvo in certain patients with chronic heart failure, and approval for KEYTRUDA
in certain types of esophageal or GEJ cancer based on KN-590, as well as approval for an alternative dosing
regimen for KEYTRUDA, dosing patients once every six weeks for combination therapies
• 	In China, received approval for KEYTRUDA in dMMR/MSI-H CRC based on KN-177 and Lynparza in certain types of
advanced prostate cancer based on PROfound
Key data presentations through July 29:
• 	Presented new data from KEYNOTE-522 in neoadjuvant and adjuvant TNBC at ESMO Virtual Plenary 2021
• 	Presented data across our broad oncology portfolio at ASCO, including for KEYTRUDA (KN-564, KN-811, KN-581,
and KN-775) and Lynparza (OlympiA), as well as first-time Phase 1 data for favezelimab (MK-4280) in MSS CRC
and updated Phase 2 data for belzutifan (MK-6482)
• 	Presented pivotal data (PNEU-AGE) and additional Phase 3 data (PNEU-AGE, PNEU-TRUE, PNEU-PATH, and
PNEU-DAY) for VAXNEUVANCE (V114) at ECCMID
• 	Presented Phase 2a data for once-monthly islatravir in HIV PrEP and Phase 2 islatravir safety analysis data in HIV
treatment at IAS
• 	Toplined results for KEYTRUDA as part of a combination regimen in certain patients with advanced TNBC (KN-
355) and in patients with advanced cervical cancer (KN-826) and VAXNEUVANCE (V114) in the pediatric setting
(PNEU-DIRECTION and PNEU-PLAN)
• 	Advanced COVID-19 antiviral, molnupiravir (MK-4482), into Phase 3 pivotal trial studying non-hospitalized
patients with at least one risk factor associated with poor disease outcomes, presented efficacy data from
inpatient and outpatient Phase 2 studies at ECCMID and initiated Phase 3 trial in the post-exposure prophylaxis
setting
4

-- 4 of 17 --

Broad and innovative pipeline to solve significant
unmet medical needs
Phase 2 	Phase 3 	Under regulatory review
Oncology
V160
Cytomegalovirus
V116
Pneumococcal, adult
V184
Chikungunya Virus
MK-1654
Respiratory Syncytial Virus
Vaccines
Infectious diseases
MK-8189
Schizophrenia
Neuroscience
Gefapixant (MK-7264)
Cough (US, JPN, EU)
Cubicin (MK-3009)
cSST & Sepsis, pediatric (JPN)
Noxafil (MK-5592)
Invasive aspergillosis (US, EU, Japan)
General medicine
General medicine
As of July 27, 2021
V114
Pneumoconjugate Vaccine, adult (EU)
Vaccines
Infectious diseases
Oncology 	Oncology
KEYTRUDA (MK-3475)
Advanced Solid Tumors
LYNPARZA (MK-7339)
Advanced Solid Tumors
MK-6440
Breast
NSCLC
SCLC
HNSCC
Esophageal
Gastric
Prostate
Melanoma
MK-1026
Hematological Malignancies
V937
Melanoma
Breast
CSCC
HNSCC
Solid Tumors
MK-7684
Melanoma
MK-5890
NSCLC
MK-6482
VHL aRCC (EU)
MK-4830
NSCLC
SCLC
MK-7075
Overgrowth Syndrome
MK-1942
Treatment Resistant Depression
MK-3655
NASH
MK-8591B (Islatravir/MK-8507)
HIV-1 Infection
KEYTRUDA (MK-3475)
Biliary Tract
Cervical (EU)
cSCC (EU)
Gastric (EU)
Hepatocellular (EU)
Mesothelioma
Ovarian
Prostate
SCLC
MK-1308A
RCC
MK-7684A
NSCLC
LENVIMA (MK-7902)
Bladder
Melanoma
NSCLC
HNSCC
Gastric
Colorectal
LYNPARZA (MK-7339)
NSCLC
SCLC
Colorectal
MK-6482
RCC
TUKYSA (MK-7119)
Breast
MK-8591A (doravirine/islatravir)
HIV-1 Infection
Islatravir (MK-8591)
HIV-1 Infection
Molnupiravir (MK-4482)
COVID-19
Belzutifan (MK-6482)
VHL-aRCC (US)
KEYTRUDA (MK-3475)
MSI-H Endometrial
TMB-H (JPN)
Unresectable or Metastatic MSI-H or dMMR Colorectal (JPN)
Metastatic TNBC (EU, JPN)
Adjuvant RCC (EU)
Advanced Unresectable Metastatic Esophageal (JPN)
LENVIMA (MK-7902)
1L HCC (US)
Advanced unresectable RCC (US, EU, JPN)
Advanced endometrial (EU, JPN)
MK-2140
Breast
NSCLC
MK-4280
NSCLC
Hematological Malignancies
MK-4280A
RCC
LENVIMA (MK-7902)
Biliary Tract
Glioblastoma
Pancreas
MK-5475
Pulmonary Arterial Hypertension
MK-1308A
Advanced Solid Tumors
HCC
CRC
Melanoma
MK-1308
NSCLC
TUKYSA (MK-7119)
Advanced Solid Tumors
Colorectal
Gastric
Endometrial
NSCLC
Bladder
BTC
Cervical
Cardiovascular
5

-- 5 of 17 --

More than tripling the number of new indications and launches
across oncology portfolio over the next eight years
6
2014-2020 	2021-2028
PIPELINE ASSETS
LENVIMA
LYNPARZA
KEYTRUDA
>90
potential approvals
expected by 2028
with more than 50
expected by 2025

-- 6 of 17 --

Oncology: continued strength & leadership across portfolio
• 	KEYTRUDA sales of $4.2B increased 20% year-
over-year, reflecting continued strong global
demand
o 	In the U.S., 15% growth driven by strong
growth across all key tumor types, including
continued leadership in lung
o 	Ex-U.S., 27% growth driven by continued
uptake in lung and ongoing launches in
HNSCC and RCC
• 	Oncology portfolio continues to benefit from
growth of Lynparza, +34%, and Lenvima, +15%
o 	Lynparza performance driven by recent
approvals
o 	Higher demand for Lenvima in China
following listing on the NRDL
1. All growth rates exclude the impact of foreign exchange. 	7
2Q20 	2Q21
+20% YOY
KEYTRUDA
2Q20 	2Q21
Lynparza
+34% YOY
2Q20 	2Q21
Lenvima
+15% YOY

-- 7 of 17 --

Vaccines: GARDASIL driving robust growth
• 	GARDASIL sales of $1.2B increased 78% year-
over-year reflecting strong underlying global
demand
o 	In the U.S., sales increased 170% year-over-
year benefitting from ongoing pandemic
recovery and strong demand
o 	Ex-U.S., sales increased 47% year-over-
year, driven by continued uptake in global
markets, including China which also
benefitted from increased supply
• 	PROQUAD-MMR-VARIVAX sales of $516M
increased 35% year-over-year, driven by
ongoing pandemic recovery in the U.S.
1. All growth rates exclude the impact of foreign exchange. 	8
2Q20 	2Q21
GARDASIL
+78% YOY
2Q20 	2Q21
PROQUAD-MMR-VARIVAX
+35% YOY

-- 8 of 17 --

Hospital: continued pandemic recovery
2Q20 	2Q21
• 	BRIDION sales of $387M increased 67%
year-over-year, reflecting higher demand
globally and improved patient access
• 	Continued uptake in PREVYMIS, driven by
ongoing launches
1. All growth rates exclude the impact of foreign exchange.
+67% YOY
9
BRIDION Performance

-- 9 of 17 --

Animal Health: very strong performance across portfolio
• 	Animal Health sales increased 27% to $1.5B,
adjusting for pandemic impact, sales
increased 19%
o 	Companion Animal sales increased 38%,
driven by increased global demand for
vaccines and parasiticides
o 	Livestock sales increased 20%,
reflecting increased global demand in
ruminant, swine and poultry, as well as
higher global demand for Animal Health
Intelligence products
1. All growth rates exclude the impact of foreign exchange. 	10
2Q20 	2Q21
+27% YOY
Animal Health

-- 10 of 17 --

Strong global recovery across geographies1
United
States
Canada
Europe 3
Latin
America
Eastern Europe /
Middle East
Africa
Japan
+3%
China
Global
pharmaceutical
sales +18%2
$343M
+18%
+42% 	+7%
+24%
+17%
+16%
Asia Pacific
+9%
11
1. Results are presented on a continuing operations basis
2. All growth rates exclude the impact of foreign exchange.
3. Europe primarily represents all European Union countries, the European Union accession markets and the United Kingdom.

-- 11 of 17 --

Q2 2021 financial results summary 1 :
Strong business recovery and leverage in P&L
Q2 2021 	Q2 2020 	Change Change
Ex-FX
Sales 	$11.4 	$9.4 	+22% 	+19%
GAAP Gross Margin 	72.8% 	70.6% 	+2% 	+3%
Non-GAAP Gross Margin 3 	76.5% 	77.1% 	-1% 	0%
GAAP net income 2 	$1.2 	$2.3 	-48% 	-47%
Non-GAAP net income
that excludes certain items 2,3 	$3.3 	$2.6 	+28% 	+27%
GAAP EPS 	$0.48 	$0.92 	-48% 	-48%
Non-GAAP EPS that excludes
certain items 3 	$1.31 	$1.02 	+28% 	+27%
$ in billions, except EPS amounts
12
1. On June 2, 2021, Merck completed the spinoff of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &
Co. (Organon) through a distribution of Organon’s publicly traded stock to company shareholders. The historical results of the women’s health, biosimilars and established brands businesses that were
contributed to Organon in the spin-off are excluded from sales and expenses and reflected as discontinued operations in the company’s Consolidated Statements of Income
2. Net income attributable to Merck & Co., Inc.
3. Merck is providing certain 2021 and 2020 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results and permits investors to understand how management
assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this release.

-- 12 of 17 --

Continuing operations full-year 2021 guidance1
1. All estimates are provided on a continuing operations basis
2. GAAP Gross Margin Rate: Higher than 2020 by a low single-digit rate
3. GAAP Operating Expenses: Lower than 2020 by a mid-single-digit rate
4. GAAP Tax Rate: ~14.5% - 15.5%
5. The GAAP to non-GAAP reconciliation is available in Merck’s Q2 2021 earnings release
Guidance 	Key Assumptions
Revenue $46.4 to $47.4B
+12% to +14% (+10% to +12% ex-FX)
• 	Raised and narrowed from previous guidance ($45.8 to
47.8B)
• 	Assumes a <2% positive FX impact
• 	Now assumes <3% negative impact due to COVID-19, all
of which relates to the pharmaceutical segment
Non-GAAP
Gross Margin Rate 2 	76.0-77.0%
Non-GAAP
Operating Expenses3 	Increase by high single-digit rate • 	Increased promotional spend and patient activation as
well as increased investment in the pipeline
Other (Income) / Expense 	~$300M of expense
Tax Rate 4 	~14.5-15.5%
Shares Outstanding 	~2.53B 	• 	Assumes very modest share repurchase
GAAP EPS 	$4.24 to $4.34
Non-GAAP EPS 5,6 	$5.47 to $5.57
+21% to +23% (+19% to +21% ex-FX) • 	Now assumes ~2% positive FX impact
13

-- 13 of 17 --

Balanced approach to capital allocation:
Investing in the business and creating value for shareholders
Capital Investments
2020 to 2024
~$ 20B
Over 5 years, including expanding manufacturing
capacity for Oncology, Vaccines, and Animal
Health. Includes >$10B in the U.S.
Over the Past 12 Months
$10.6
Billions
ORDER OF
PRIORITY
Commitment to the Dividend
14
• 	$9.7 billion invested in R&D (~$8.3 billion after-tax)
• 	$8.8 billion spent on business development, including recently
closed Pandion Therapeutics acquisition
• 	$6.6 billion in dividend and share repurchases
o 	Remain committed to the dividend, which increased
7% in 2021
o 	Returned $0.2 billion in Q2 2021 through share
repurchases
Balanced Capital Allocation to Invest in Growth While
Returning Cash to Shareholders Over Past 12 Months
$1.72 	$1.76 	$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44 $2.60
$1.40
$1.70
$2.00
$2.30
$2.60
2013 	2014 	2015 	2016 	2017 	2018 	2019 	2020 	2021E
Dollars per share
+11% 	+2% 	+2% 	+2% 	+2% 	+2%
+11%
+15%
+7%
$10.6
$8.3
$5.0
$6.6
$8.8
$0
$2
$4
$6
$8
$10
After-Tax R&D 	CapEx 	Dividends &
Share Repurchase
Business
Development
(ex-divestitures)

-- 14 of 17 --

Merck has actively supplemented its pipeline and portfolio with
strategic business development
15
Oncology 	Cardiovascular,
Neurosciences & Other
Animal Health
Bolt-on acquisitions
Strategic
collaborations
& licensing

-- 15 of 17 --

Creating long-term value for patients, employees and shareholders
Working with more speed, urgency and agility to more closely match
the pace of change in the broader environment, and accelerate delivery
of our innovations to the patients who need them
Next 5 Years
Strong execution driving
sustainable revenue growth,
meaningful margin expansion and
accelerated bottom-line growth
5-10 Years
Rich pipeline addressing
areas of high unmet need to
drive performance over the
next 5 to 10 years
10+ Years
Revitalized discovery efforts and
increased expertise in biology to
deliver ongoing scientific
breakthroughs for decades to come
16

-- 16 of 17 --

Continuing to make progress on our ESG commitments
17
Renewable Energy
Accelerating by 15 years, to
2025, our goal to 100%
renewable energy sources of
our purchased electricity
Carbon Neutrality
Committed to achieving
carbon neutrality across our
operations by 2025 and
reducing our value chain
emissions 30% by 2030
46% Female
Increased the gender
diversity of our Board of
Directors
Access Principles
Refreshed our Access to
Health Guiding Principles to
ensure we continue to
prioritize affordable
availability and uptake of our
medicines and vaccines
COVID-19 Relief
Provided more than $30
million for relief efforts in
2020, including cash support
and in-kind giving, to help
address the COVID-19
pandemic’s impact on
vulnerable people and
communities
13 million Women
Reached 13 million women
through Merck for Mothers,
which promotes safe, high-
quality healthcare to help
prevent maternal mortality
1 million
Announced that our prior
CEO, Ken Frazier, is the co-
chair of the OneTen
Initiative, which is working
toward the hiring and
promoting of 1M Black
Americans over the next 10
years
267 million
Reached more than 267
million people globally with
product donations through
the MECTIZAN® Donation
Program and Medical
Outreach Program

-- 17 of 17 --